Healthcare Industry News: Ortho Biotech Products
News Release - March 6, 2006
Tibotec Announces FDA Acceptance for Review of NDA for TMC114CORK, Ireland, March 6 (HSMN NewsFeed) -- Tibotec Pharmaceuticals Ltd. today announced that the New Drug Application (NDA) for TMC114, an investigational HIV protease inhibitor, has been accepted for priority review by the United States Food and Drug Administration (FDA). The Prescription Drug User Fee Act (PDUFA) user fee goal date for the NDA will be June 23, 2006.
The NDA is based on the efficacy and safety results of the 24 week analysis of two randomized, controlled studies, POWER 1 and POWER 2, and supportive open label safety data from POWER 3. The POWER 1 data were presented at the International AIDS Society (IAS) conference in Rio de Janeiro in July 2005. The POWER 2 data were presented in December at the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Washington D.C.
Phase III clinical trials of TMC114, boosted with low-dose ritonavir, are currently ongoing in both treatment-experienced and treatment-naive HIV-1 infected patients. TMC114 is available through an expanded access program (EAP) in the United States for people living with HIV who need the compound to construct a viable treatment regimen and who are not eligible for other Tibotec clinical trials. For more about the program, healthcare professionals and people living with HIV/AIDS may obtain information by visiting www.tibotec.com or www.clinicaltrials.gov.
Pending US regulatory approval, Tibotec Therapeutics, a division of Ortho Biotech Products, L.P., will commercialize the product in the U.S. The trade name for the marketed product has not yet been determined.
Tibotec Pharmaceuticals Ltd.: Research & Development
Tibotec Pharmaceuticals Ltd., based in Cork, Ireland, is a pharmaceutical research and development company. The Company's main research and development facilities are in Mechelen, Belgium with offices in Yardley, PA. Tibotec is dedicated to the discovery and development of innovative HIV/AIDS drugs and anti-infectives for diseases of high unmet medical need.
Tibotec Therapeutics: US Sales & Marketing
Tibotec Therapeutics, a division of Ortho Biotech Products, L. P., is headquartered in Bridgewater, N.J., and is dedicated to delivering innovative virology and other specialty therapeutics that help healthcare professionals improve patients' survival and quality of life, and address serious unmet needs in the health care community.
For further information, please visit: www.tibotec.com
Source: Tibotec Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.